فعالية الكارفيديلول و سلامته في الاعتلال التوسعي للعضلة القلبية عند الأطفال

Abstract EN

Background & Objective: Dilated Cardiomyopathy is characterized by dilated and contractile dysfunction of left ventricle, is defined in terms of Hemodinamically by a decrease in left ventricle ejection fraction less than 50%.To evaluated the clinical effect of Carvedilol among pediatric patients with dilated cardiomyopathy (DCM) who did not responded to standard therapy.

Methods & Materials: we performed a prospective study over 3 years in 15 Children (10 male , 5 female) – the mean age was (34.7±5) months (range: 5 months- 9 years), all had been treated with conventional medications (digoxin, diuretics, angiotensin-converting enzyme inhibitors) for more than 3 months before starting Carvedilol.

All patients received an initial dose of 0.05 mg/kg/day in two divided doses.

Cardevilol dose was increased weekly to achieve 1.2 mg/kg/day in 6 months.

Left ventricular function on echocardiography (EF,FS,VCFc) was obtained before and during Carvedilol therapy, in addition to modified ROSS score and modified New York Heart Association functional class in children, at follow up of six months Results: The modified ROSS score improved in (12) patients (80)%.

Left ventricular EF, Left ventricular FS and VCFc improved from 26.8±8% to 41.7±18% and from 14.8±3% to 21±9% and from 0.52±0.05 circ/s to 0.76±0.14 circ/s respectively.

Conclusion: the results of present study indicate that Carvedilol improves ventricular function and symptoms in children with DCM, it is well tolerated with minimal adverse effects.